Developing novel blood-based biomarkers for Alzheimer's disease

Heather M. Snyder, Maria C. Carrillo, Francine Grodstein, Kim Henriksen, Andreas Jeromin, Simon Lovestone, Michelle M. Mielke, Sid O'Bryant, Manual Sarasa, Magnus Sjøgren, Holly Soares, Jessica Teeling, Eugenia Trushina, Malcolm Ward, Tim West, Lisa J. Bain, Diana W. Shineman, Michael Weiner, Howard M. Fillit

Research output: Contribution to journalArticlepeer-review

99 Scopus citations


Alzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant discussion, including potential next steps to move this area of research forward.

Original languageEnglish (US)
Pages (from-to)109-114
Number of pages6
JournalAlzheimer's and Dementia
Issue number1
StatePublished - Jan 2014
Externally publishedYes


  • Alzheimer's disease
  • Biomarker
  • Blood based biomarker
  • Diagnostics
  • Early detection
  • Early diagnosis

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology


Dive into the research topics of 'Developing novel blood-based biomarkers for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this